<DOC>
	<DOCNO>NCT02229799</DOCNO>
	<brief_summary>The objective study review safety efficacy Actilyse Vial ( hereafter refer `` Actilyse '' ) post-marketing use treatment acute ischemic stroke , investigate following ; 1 . Unknown adverse event ( especially serious adverse event ) 2 . Frequency ( Incidence ) trend adverse event actual practice 3 . Factors safety profile Actilyse 4 . Factors efficacy profile Actilyse</brief_summary>
	<brief_title>Protocol Post Marketing Surveillance Actilyse Vial</brief_title>
	<detailed_description />
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>All in/out patient diagnose acute ischemic stroke 1 . Actilyse administer patient high risk follow : Significant bleed disorder present within past 6 month , know hemorrhagic diathesis Patients receive oral anticoagulant , e.g . warfarin sodium ( INR &gt; 1.3 ) Manifest bleed recent severe dangerous bleed History evidence suspicion intracranial hemorrhage include subarachnoid hemorrhage Any history central nervous system damage ( i.e . neoplasm , aneurysm , intracranial spinal surgery ) Hemorrhagic retinopathy ( e.g . diabetes , vision disturbance may indicate hemorrhagic retinopathy ) hemorrhagic ophthalmic condition Prolonged traumatic cardiopulmonary resuscitation ( &gt; 2 minute ) , obstetrical delivery , within past 10 day , recent puncture noncompressible bloodvessel ( e.g . subclavian jugular vein puncture ) Severe uncontrolled arterial hypertension Bacterial endocarditis pericarditis Acute pancreatitis Documented ulcerative gastrointestinal disease within past 3 month , oesophageal varix , arterialaneurysms , arterial/venous malformation Neoplasm increase bleed risk Severe hepatic dysfunction , include hepatic failure , cirrhosis , portal hypertension ( oesophageal varix ) active hepatitis Hypersensitive active substance alteplase excipients 2 . In case acute myocardial infarction acute pulmonary embolism , history stroke contraindicate . 3 . In case Actilyse administer acute ischaemic stroke , following contraindicate : Symptoms ischemic attack begin 3 hour prior infusion start time symptom onset unknown , Symptoms acute ischemic stroke either rapidly improve minor start infusion Severe stroke assess clinically and/or appropriate imaging technique , Seizure onset stroke Evidence intracranial hemorrhage ( ICH ) CTscan Symptoms suggestive subarachnoid hemorrhage , even CTscan normal Administration heparin within 48 hour precede onset stroke elevate activated partial thromboplastin time ( aPTT ) presentation A combination previous stroke diabetes mellitus Prior stroke head trauma within past 3 month Platelet count le 100,000/mm3 Systolic blood pressure &gt; 185 mm Hg , diastolic blood pressure &gt; 110 mm Hg , aggressive management ( IV medication ) necessary reduce blood pressure limit Blood glucose &lt; 50mg/dl &gt; 400 mg/dl 4 . Acute stroke patient age ≤ 18 ≥ 80 year</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>